TB-Bs1 is a first-in-class T-cell Engaging (TCE) bispecific antibody built on the DuoBody™ platform targeting ROR2. ROR2 is a receptor that has been shown to cause cancer cell proliferation and that ...
Ozuriftamab vedotin, the Company’s conditionally and reversibly active antibody drug conjugate directed against ROR2, has shown promising clinical activity with a manageable safety profile in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results